Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension
Abstract Background This was a phase 3, randomized, double-blind, placebo-controlled study. Methods Adult Korean patients with essential hypertension and a baseline mean sitting clinic systolic blood pressure (scSBP) ≥150 and ≤180 mmHg were randomized to 6-week treatment with placebo (n = 65), azils...
Main Authors: | Attila Juhasz, Jingtao Wu, Michie Hisada, Tomoka Tsukada, Myung Ho Jeong |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-02-01
|
Series: | Clinical Hypertension |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40885-018-0086-4 |
Similar Items
-
Full spectrum and genetic algorithm-selected spectrum-based chemometric methods for simultaneous determination of azilsartan medoxomil, chlorthalidone, and azilsartan: Development, validation, and application on commercial dosage form
by: Darwish Hany W., et al.
Published: (2021-03-01) -
MODERN OPPORTUNITIES FOR ANTIHYPERTENSION THERAPY: THE PLACE OF AZILSARTAN MEDOXOMIL
by: V. V. Skibitsky, et al.
Published: (2017-12-01) -
The possibility of a new receptor blocker to angiotensin in improving control of hypertension. Non-intervention international multicenter observational prospective study of the use azilsartan medoxomil in patients with arterial hypertension and overweight or obesity in the Russian Federation and the Republic of Kazakhstan
by: Yu V Zhernakova, et al.
Published: (2016-09-01) -
The possibility of a new receptor blocker to angiotensin in improving control of hypertension. Non-intervention international multicenter observational prospective study of the use azilsartan medoxomil in patients with arterial hypertension and overweight
by: Zhernakova Yu.V., et al.
Published: (2016-12-01) -
Efficacy and safety of azilsartan medoxomil in various doses in patients with metabolic disorders
by: Nikita B. Perepech, et al.
Published: (2021-10-01)